OncoVista Innovative Therapies Inc
OncoVista Innovative Therapies, Inc., a biopharmaceutical company, develops targeted anticancer therapies by utilizing tumor-associated biomarkers. The company's product candidates include Cordycepin (OVI-123), which is in Phase I/II clinical trials for the treatment of refractory TdT positive leukemias; and L-Nucleoside Conjugates (OVI-117) that is under pre-clinical development for the treatmen… Read more
OncoVista Innovative Therapies Inc (OVIT) - Total Assets
Latest total assets as of September 2015: $61.27K USD
Based on the latest financial reports, OncoVista Innovative Therapies Inc (OVIT) holds total assets worth $61.27K USD as of September 2015.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
OncoVista Innovative Therapies Inc - Total Assets Trend (2000–2014)
This chart illustrates how OncoVista Innovative Therapies Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
OncoVista Innovative Therapies Inc - Asset Composition Analysis
Current Asset Composition (December 2014)
OncoVista Innovative Therapies Inc's total assets of $61.27K consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 100.0% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2000–2014)
This chart illustrates how OncoVista Innovative Therapies Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: OncoVista Innovative Therapies Inc's current assets represent 100.0% of total assets in 2014, an increase from 0.0% in 2000.
- Cash Position: Cash and equivalents constituted 100.0% of total assets in 2014, up from 82.1% in 2000.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2000.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
OncoVista Innovative Therapies Inc Competitors by Total Assets
Key competitors of OncoVista Innovative Therapies Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
OncoVista Innovative Therapies Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - OncoVista Innovative Therapies Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - OncoVista Innovative Therapies Inc is currently not profitable relative to its asset base.
OncoVista Innovative Therapies Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.01 | 0.03 | 0.04 |
| Quick Ratio | 0.01 | 0.03 | 0.04 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-5.89 Million | $ -4.09 Million | $ -5.67 Million |
OncoVista Innovative Therapies Inc - Advanced Valuation Insights
This section examines the relationship between OncoVista Innovative Therapies Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 26.09 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -87.0% |
| Total Assets | $12.51K |
| Market Capitalization | $1.00 USD |
Valuation Analysis
Below Book Valuation: The market values OncoVista Innovative Therapies Inc's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: OncoVista Innovative Therapies Inc's assets decreased by 87.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for OncoVista Innovative Therapies Inc (2000–2014)
The table below shows the annual total assets of OncoVista Innovative Therapies Inc from 2000 to 2014.
| Year | Total Assets | Change |
|---|---|---|
| 2014-12-31 | $12.51K | -87.01% |
| 2013-12-31 | $96.32K | -83.26% |
| 2012-12-31 | $575.27K | -73.72% |
| 2011-12-31 | $2.19 Million | -38.35% |
| 2010-12-31 | $3.55 Million | +765.59% |
| 2009-12-31 | $410.14K | -25.98% |
| 2008-12-31 | $554.13K | -88.81% |
| 2007-12-31 | $4.95 Million | +10001.94% |
| 2006-12-31 | $49.00K | -37.48% |
| 2005-12-31 | $78.37K | +33.58% |
| 2004-12-31 | $58.67K | -0.56% |
| 2003-12-31 | $59.00K | +2850.00% |
| 2002-12-31 | $2.00K | -89.47% |
| 2001-12-31 | $19.00K | -93.58% |
| 2000-12-31 | $296.00K | -- |